Figure 3.

Kaplan-Meier curves for disease-free survival (DFS) in tamoxifen-treated patients according to the HER family receptor and PgR status. Among tamoxifen-treated patients with ER+/PR+ tumors, neither EGFR (HER1) nor HER2 had a significant effect on DFS, although there was a suggestion of a trend in HER2-positive tumors. In contrast, among patients whose tumors were ER+/PR−, both EGFR and HER2 expression were associated with significantly poorer DFS (for HER-1, HR = 2.4, 95% CI = 1.0 to 5.4, P = 0.04; and for HER2, HR = 2.6, 95% CI = 1.1 to 6.0, P = 0.03). [Adapted with permission of Oxford University Press from Arpino et al. (147).]